

## DAFTAR PUSTAKA

1. Arimbawa IM, Himawan IW, Pulungan AB, Rini EA, Marzuki NS, Batubara JR. Panduan praktik klinis osteogenesis imperfecta. Jakarta: Badan Penerbit Ikatan Dokter Anak Indonesia, 2017.
2. Starr SR, Roberts TT, Fischer PR. Osteogenesis imperfecta: primary care. *Pedsinreview*. 2010;31(8):e54-64.
3. Rousseau M, Retrouvey J. Osteogenesis imperfecta: potential therapeutic approaches. *Peer J*. 2018;6:e5464.
4. Machol K, Hadley T, Schmidt J, Cuthbertson D, Traboulsi H, Silva R et al. Hearing loss in individuals with osteogenesis imperfecta in North America: Results from a multicenter study. *Am J Med Genet*. 2019;182(4):697-704.
5. Biggin A, Munns C. Osteogenesis Imperfecta: *Curr Osteoporos Rep*. 2014;12(3):279-288.
6. Van Dijk F, Sillence D. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment. *Am J Med Genet*. 2014;164(6):1470-1481.
7. Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents—new developments in diagnosis and treatment. *Osteoporos Int*. 2016;27(12):3427-3437.
8. Shi J, Ren M, Jia J, Tang M, Guo Y, Ni X et al. Genotype–Phenotype Association Analysis Reveals New Pathogenic Factors for Osteogenesis Imperfecta Disease. *Front. Pharmacol*. 2019;10.
9. Moosa S, Yamamoto G, Garbes L, Keupp K, Beleza-Meireles A, Moreno C et al. Autosomal-Recessive Mutations in MESD Cause Osteogenesis Imperfecta. *Am J Hum Genet*. 2019;105(4):836-843.
10. Van Dijk F, Cobben J, Kariminejad A, Maugeri A, Nikkels P, van Rijn R et al. Osteogenesis Imperfecta: A Review with Clinical Examples. *Mol Syndromol*. 2011;.
11. Tjahjono HA, Aditiawati, Pulungan AB, Marzuki NS, Rini EA, Himawan IW, Batubara JR. Panduan praktik klinis perawakan pendek pada anak dan remaja di Indonesia. Trejo P, Rauch F. Osteogenesis imperfecta in children and adolescents—new developments in diagnosis and treatment. *Osteoporos Int*.

2016;27(12):3427-3437.

12. Marr C, Seasman A, Bishop N. Managing the patient with osteogenesis imperfecta: a multidisciplinary approach. *J Multidiscip Healthc.* 2017; 10:145-155.
13. Mulati E, Kaptiningsih A, Suryantan J. Pedoman Pencegahan dan Tatalaksana Gizi Buruk pada Balita. 1st ed. Jakarta: Kementerian Kesehatan Republik Indonesia; 2019.
14. Graff K, Syczewska M. Developmental charts for children with osteogenesis imperfecta, type I (body height, body weight and BMI). *Eur J Pediatr.* 2017;176(3):311-316.
15. Gerber R, Wilks T, Erdie-Lalena C. Developmental Milestones: Motor Development. *Pedsinreview.* 2010;31(7):267-277.
16. Balasubramanian M, Hobson E, Skae M, McCaughey J, Stephens D. Developing pathways to clarify pathogenicity of unclassified variants in Osteogenesis Imperfecta genetic analysis. *Mol Genet Genomic Med.* 2019;7(12).
17. Michell C, Patel V, Amirfeyz R, Gargan M. Osteogenesis imperfecta. *Curr Orthop Pract.* 2007;21:236-41
18. American Academy of Pediatrics. Council on children with disabilities. identifying infants and young children with developmental disorders in the medical home: an algorithm for developmental surveillance and screening. *AAP.* 2006;118:405-19.
19. Engelbert RH, Uiterwaal CS, Gulmans VA, Pruijs HE, Helders PJ. Osteogenesis imperfecta: profiles of motor development as assessed by a postal questionnaire. *Eur J Pediatr.* 2000;159:615-20.
20. Harnas L, Marini J. Neurologic Profile in Osteogenesis Imperfecta. *Connect Tissue Res.* 1995;31(sup4):s23-s26.
21. Major P, Thiele EA. Seizure in children: laboratory, diagnosis, and management. *Pediatr Rev.* 2007;28:405- 14.
22. Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population based case control study. *Lancet Neurol* 2007;6:693-8. 11.
23. Khreisat WH. Clinical profile of epilepsy during the two years of life. *Pak J Med Sci* 2006;22:55-9.
24. Gjergja Juraški R, Turkalj M, Mikula I, Primorac D. eurologic manifestations and

- sleep issues in osteogenesis imperfecta. *Paediatr Croat.* 2020;61:113-121.
25. Panaylotopoulus. Clinical aspects of the diagnosis of epileptic seizures and epileptic syndromes. *The epilepsies: seizures, syndromes and management.* Bladon Med Publ;2005.h.1-28
  26. Adhim M, B. Bober M. Vitamin D Status in Pediatric Patients with Osteogenesis Imperfecta. *Pediatr Therapeut.* 2011;01(02).
  27. Holick M. Vitamin D Deficiency. *O.* 2007;357(3):266-281.
  28. Plante L, Veilleux L, Glorieux F, Weiler H, Rauch F. Effect of high-dose vitamin D supplementation on bone density in youth with osteogenesis imperfecta: A randomized controlled trial. *Bone.* 2016;86:36-42
  29. Kadhim M, B. Bober M. Vitamin D Status in Pediatric Patients with Osteogenesis Imperfecta. *Pediatr Therapeut.* 2011;01(02).
  30. Abukabbos H, Al-Sineedi F. Clinical manifestations and dental management of dentinogenesis imperfecta associated with osteogenesis imperfecta: Case report. *Saudi J Dent Res.* 2013;25(4):159-165.
  31. Otaify G, Aglan M, Ibrahim M, Elnashar M, El Banna R, Temtamy S. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study. *Osteoporos Int.* 2015;27(1):81-92.
  32. Pavón de Paz I, Rosado Sierra J, Pérez Blanco C, Modroño Móstoletos N, Guijarro de Armas G, Navea Aguilera C. Efectos agudos y a largo plazo del tratamiento con zolendronato en pacientes adultos con osteogénesis imperfecta. Estudio español observacional con 5 años de seguimiento. *Endocrinología, Diabetes y Nutrición.* 2019;66(2):108-116.
  33. Vuorimies I, Toiviainen-Salo S, Hero M, Mäkitie O. Zoledronic Acid Treatment in Children with Osteogenesis Imperfecta. *Horm Res Paediatr.* 2011;75(5):346-353.
  34. Kumar C, Panigrahi I, Somasekhara Aradhya A, Meena B, Khandelwal N. Zoledronate for Osteogenesis imperfecta: evaluation of safety profile in children. *J Pediatr Endocrinol Metab.* 2016;29(8).
  35. Zambrano MB, Brizola ES, Refosco L, Giugliani R, Felix TM. Anthropometry, nutritional status, and dietary intake in pediatric patients with osteogenesis imperfecta. *J Am Coll Nutr.* 2014;33(1):18-25.
  36. Chagas C, Roque J, Santarosa Emo Peters B, Lazaretti-Castro M, Martini L. Do patients with osteogenesis imperfecta need individualized nutritional support?. *Nutrition.* 2012;28(2):138-142.



37. Vetter U, Pontz B, Zauner E, Brenner RE, Spranger J (1992) Osteogenesis imperfecta: a clinical study of the first ten years of life. *Calcif Tissue Int* 50: 36±41
38. Tsimicalis A, Denis-Larocque G, Michalovic A, Lepage C, Williams K, Yao T et al. The psychosocial experience of individuals living with osteogenesis imperfecta: a mixed-methods systematic review. *Qual Life Res*. 2016;25(8):1877-1896.
39. Dogba M, Bedos C, Durigova M, Montpetit K, Wong T, Glorieux F et al. The impact of severe osteogenesis imperfecta on the lives of young patients and their parents – a qualitative analysis. *BMC Pediatrics*. 2013;13(1).
40. Hill C, Baird W, Walters S. Quality of life in children and adolescents with Osteogenesis Imperfecta: a qualitative interview based study. *Health Qual Life Out*. 2014;12(1):54.
41. Bowden, S. and Mahan, J., 2017. Zoledronic acid in pediatric metabolic bone disorders. *Translational Pediatrics*, 6(4), pp.256-268.
42. Hamza R, Abdelaziz T, Elakkad M. Anthropometric and Nutritional Parameters in Egyptian Children and Adolescents with Osteogenesis Imperfecta. *Hormone Research in Paediatrics*. 2015;83(5):311-320.
43. Zambrano MB, Brizola ES, Refosco L, Giugliani R, Félix TM: Anthropometry, nutritional status, and dietary intake in pediatric patients with osteogenesis imperfecta. *J Am Coll Nutr* 2014;33:18–25.
44. Riswanto B, Bayusentono S. Quality of Life Evaluation in Children With Osteogenesis Imperfecta After Giving Bisphosphonate Infusion in Dr. Soetomo Hospital Surabaya. *Medical and Health Science Journal*. 2020;4(1):34-38.
45. Hill M, Lewis C, Riddington M, Crowe B, DeVile C, Götherström C et al. Exploring the impact of Osteogenesis Imperfecta on families: A mixed-methods systematic review. *Disability and Health Journal*. 2019;12(3):340-349.
46. Xu H, Zhao Z, Wang H, Ding M, Zhou A, Wang X et al. Bone Mineral Density of the Spine in 11,898 Chinese Infants and Young Children: A Cross-Sectional Study. *PLoS ONE*. 2013;8(12):e82098.
47. Cho T, Ko J, Kim H, Shin H, Yoo W, Shin C. Management of Osteogenesis Imperfecta: A Multidisciplinary Comprehensive Approach. *Clinics in Orthopedic Surgery*. 2020;12(4):417.
48. Carmel A, Shieh A, Bang H, Bockman R. The 25(OH)D level needed to maintain a favorable bisphosphonate response is  $\geq 33$  ng/ml. *Osteoporosis International*. 2012;23(10):2479-2487.